Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Leukemia & Lymphoma|November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie HospitalMary Gleeson, Clare Peckitt, David Cunningham, et al.
Circulation. Heart Failure|June 29, 2022
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline CardiotoxicityPeter A Henriksen, Peter Hall, Olga Oikonomidou, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
Blood Advances|May 10, 2023
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project NetworkGreg Hapgood, Monica Civallero, Yana Stepanishyna, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
Blood|March 6, 2012
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyMyron S Czuczman, Luis Fayad, Vincent Delwail, et al.
Pageof 11